Latest News & Features
Generics
Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again. 9 December 2021
Generics
Teva Pharmaceuticals has failed to convince the US Court of Appeal for the Federal Circuit that a Corcept Therapeutics method patent for Korlym was invalid. 9 December 2021
Americas
Mylan has been allowed to revisit a decision holding that it infringed patents covering AstraZeneca's inhaler asthma treatment, Symbicort. 9 December 2021
article
Patent linkage is a complex issue as it amalgamates the protection of IP with the remit of drug regulators in varying jurisdictions. The scope of this interaction varies in different countries and pharmaceutical companies need to know which jurisdictions adopt a patent linkage regime when they decide whether to adopt an enforcement strategy or seek regulatory approval for a new product. 9 December 2021
Americas
Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal. 7 December 2021
Generics
Galderma Laboratories has sued Lupin Pharmaceuticals alleging that it plans to manufacture and sell a generic version of Oracea prior to the expiration of key patents. 7 December 2021
Americas
Johnson & Johnson’s subsidiary Ethicon has obtained a permanent injunction against counterfeiters selling fake versions of Surgicel, an absorbable haemostat used to control bleeding during surgery. 7 December 2021
article
From the old theory that medical costs will destroy a nation to the recent theory that Opdivo do the same, balancing a national health insurance system with medical finances has been an urgent issue. 3 December 2021
article
Life sciences innovators at all stages seek patent protection to limit market competition and, in some cases, attract further investment. Careful IP planning is especially important in the life sciences, with many companies relying on a handful of patents to protect their high-value products. It is essential that companies pay close attention to the interrelationship between patent and US Food and Drug Administration regulatory considerations to protect their most valuable assets for the long term. 2 December 2021
Americas
Illumina has secured an $8 million damages verdict against China-based BGI Genomics, and its US subsidiary, MGI, in a dispute involving gene-sequencing patents. 2 December 2021